RE: Sajy19 Dec 2023 05:55
I don’t need to explain how it’s valued it’s not a revenue stock so asking me how I valued it is another pointless/useless message!
It has 2 late stage de-risked assets with substantial market opportunity NCTD-M3 has a market opportunity of $500m deal already in place and XF-73 Nasal has a market opportunity of $2 billion for the US alone
Then they’ve got XF-73 platform and XF-73 Dermal that are longer term opportunities
We are only at 79p due to a market sell off, previously £1.80 and now a lot further down the pipeline, 3 broker targets of over £2.80 excluding the deal soon to be announced on XF-73 Nasal.
Added onto all that is the new leadership with a significant CV in the pharma industry taking GW to over a billion dollar market cap and stated he’s more excited of what we’ve got here than what he had when he joined GW
So a price of over £2 on deal announcement is easily achieved IMHO